Background
==========

Alpha-human papillomaviruses (HPV) are sexually transmitted and may infect the anogenital and oral mucosae. They either resolve without sequelae or cause condyloma (HPV types 6 and 11 and their relatives) or rarely carcinoma, particularly cervical cancer and its precursors (cervical intraepithelial neoplasia, CIN). HPV16 and 18 account for 70% to 80% of cervical cancers with the remainder due to other alpha- HPV genotypes. HPV are labeled high-risk (HR-HPV) if found in cancers in disproportion to their prevalence; uncertainty exists as to whether certain genotypes (e.g., HPV26, 53, 70, 73 and 82) should be classified as high-risk.

Cervical carcinogenesis depends on the deregulation of HPV *E6/E7*in cell nuclei as dysplasia progresses. Although no \"gold standard\" for type-specific HPV genotyping has been agreed upon, current methods generally employ the polymerase chain reaction (PCR) with consensus primers aimed at the *L1*capsid gene \[[@B1]\], despite the fact that it is the *E6/E7*genes which are most reliably conserved in cervical cancer \[[@B2]\]. The type-specific *E6/E7*junction is also less prone to sequence variation than other genes, which like the capsid genes may be lost during integration of viral DNA into the host cell genome \[[@B2]-[@B5]\].

By combining labeled *E6/E7*primers in a multiplex PCR (MPCR) to yield products which are size and color-specific for each HPV genotype on capillary electrophoresis, the need for nested PCR, amplicon sequencing, probe hybridization or enzymatic detection steps \[[@B6]\] and specialized equipment is obviated. MPCR targeting these type-specific oncogenes has been reported but the methods may use proprietary technology not widely available and require additional post-PCR treatments, making them less suitable for small specimen volumes in the pathology laboratory \[[@B6],[@B7]\]. Capillary electrophoresis, on the other hand, is well established, widely available for fragment size analysis and it yields reproducible size peaks with a tolerance of ± 0.5 nucleotide (nt). We describe a single-tube straightforward *E6/E7*MPCR capable of detecting 19 HR-HPV in a test set of highly significant lesions (CIN 2 to carcinoma) submitted as cytology specimens, including aspirates from metastases, as well as fresh and formalin-fixed tumor embedded in paraffin (FFPE).

Results
=======

We targeted in a single microfuge tube 19 definite or probable HR-HPV genotypes (HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82) \[[@B8],[@B9]\] and in addition low-risk (LR) HPV6 and 11 and as a control the human β-globin gene. Table [1](#T1){ref-type="table"} lists the accession numbers of the HPV targets in GenBank, primer sequences, labels, true amplicon sizes and their observed electrophoretic sizes. Template DNA came from five sources: (i) long oligonucleotides mimicking *E6/E7*targets (except for HPV types 16, 51 and 73) for determination of electrophoretic product size, (ii) for analytical sensitivity a test panel of 14 plasmid-cloned HPV genotypes \[[@B10]\], courtesy of the WHO HPV Reference Lab, Malmö, Sweden, (iii) for clinical sensitivity, DNA extracted from 500 μL of pelleted cellular material in PreservCyt solution^®^used for ThinPrep cytology (Cytyc, USA), which specimens were obtained with a cytobrush (N = 97, including 37 consecutive normal, 13 atypical, 39 dysplasias and 9 cancers), (iv) FFPE specimens (N = 44, including 11 cervical dysplasias and 33 cancers) and (v) Indicating FTA Microcards^®^(Whatman, Germany) with imprinted cut tumor surface or applied swabs/aspirates (N = 64, including 30 primary cervical carcinomas and 3 nodal metastases, in addition to 31 aspirates of nodal metastases from head and neck SCC). FTA cards significantly expedite sample collection, storage and preparation and have been described previously in lymphoma MPCR \[[@B11]\]. Patient specimens were de-identified to conform to the ethical guidelines established at our institution.

###### 

HPV primer and product characteristics

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  HPV type   **Genbank accession no**.                                     E6/E7 Primers^1^                                   Product\'s\   Product\'s\
                                                                                                                              molecular\    electrophoretic\
                                                                                                                              size (nt)     size (nt)^2^
  ---------- --------------------------- --------------------------------- ------------------ ------------------------------- ------------- ------------------
                                         **Forward**                       **5\' label**      **Reverse**                                   

  39         [M62849](M62849)            ACA GTG TCG ACG GTG CTG GA        FAM                GCT TTG GTC CAC GCA TAT CTG A   94            92

  70         [U21941](U21941)            ACA GTG CCG ACA CTG CTG GA        NED                GGC CGT GGT CCA TGC ATA TT      95            94

  68         [Y14519](Y14519)            ACA GTG TCG **S**CA CTG CTG GA    HEX                GGG CTT TGG TCC ATG CAT AGT     95            95

  18         [X05015](X05015)            AGT GCC ATT CGT GCT GCA AC        FAM                ATG TTG CCT TAG GTC CAT GCA T   98            96

  56         [X74483](X74483)            TGG TTG GAC CGG GTC ATG T         HEX                CGT CTT GCA GCG TTG GTA CTT T   103           100

  45         [X74479](X74479)            GGA CAG TAC CGA GGG CAG TGT A     NED                CCG GGG TCC ATG CAT ACT TAT     107           106

  33         [M12732](M12732)            AAT ATT TCG GGT CGT TGG GC        FAM                AAC GTT GGC TTG TGT CCT CTC A   109           107

  35         [M74117](M74117)            GGT GGA CAG GTC GGT GTA TGT C     HEX                GTT GCC TCG GGT TCC AAA TC      120           116

  66         [U31794](U31794)            ACC GGG TCA TGT TTG CAG TGT       NED                CGT TTG CGG TGC AAG TTC TAA T   122           120

  6/6b       [AF092932](AF092932)\       CCA AGG C**R**C GGT TCA TAA AGC   FAM                GGG TCT GGA GGT TGC AGG TCT A   123           120
             [X00203](X00203)                                                                                                               

  6a         [L41216](L41216)            CCA AGG CGC GGT TTA TAA AGC       FAM                GGG TCT GGA GGT TGC AGG TCT A   123           120

  31         [J04353](J04353)            GTG GAC AGG ACG TTG CAT AGY A     HEX                GGT CAG TTG CCT CAG GTT GCA     124           121/203^3^

  26         [X74472](X74472)            GGG CAG TGG AAA GGG TTG TGT       NED                GGT TGC GGC ACC AGA TCT AGT A   128           126

  51         [M62877](M62877)            AAT GCG CTA ATT GCT GGC AA        HEX                TGC TCG TAG CAT TGC AAG TCA A   143           142

  53         [X74482](X74482)            ATA TGT GGA CCG GGT CGT GC        FAM                GGC ATT GCA GGT CAA TCT CAG T   143           143

  82         [AB027021](AB027021)        ACG GGA CAG TGT GCA AAT TGC       HEX                TGC TCG TAG CAT TGC AAG TCA A   150           150

  52         [X74481](X74481)            GTT GGA CAG GGC GCT GTT C         NED                CCT CCT CAT CTG AGC TGT CAC C   166           167

  59         [X77858](X77858)            ACA GTG TCG TGG GTG TCG GA        FAM                TGC TCG TAG CAC ACA AGG TCA A   169           169

  58         [D90400](D90400)            AGG GCG CTG TGC AGT GTG T         HEX                CAT CCT CGT CTG AGC TGT CAC A   172           172

  11         [M14119](M14119)            GGG AAA GGC ACG CTT CAT AAA       NED                TGT CCA CCT TGT CCA CCT CAT C   190           190

  16         [K02718](K02718)            GTG GAC CGG TCG ATG TAT GTC T     HEX                TCC GGT TCT GCT TGT CCA GC      209           210

  73         [X94165](X94165)            AAC AGT GGA CCG GAC GCT GT        FAM                GGC AAG GCA TAC TGT GCA CTG A   258           260

  β-globin   [NG000007](NG000007)        GAA GAG CCA AGG ACA GG TAC        HEX                CAA CTT CAT CCA CGT TCA CC      268           268
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Each ambiguous base code S, R and Y yields two different primer sequences. HPV types 51 and 82 share identical reverse primers.

^2^Default colors: FAM, blue; NED, black; HEX, green.

^3^Secondary HEX peak at 203 nt is due to cross-annealing to the HPV16 reverse primer.

Results in clinical material are presented in Table [2](#T2){ref-type="table"}. All 19 HR-HPV were detected in at least one and most in more than two clinical samples with as many as five genotypes observed in a single specimen (Figure [1](#F1){ref-type="fig"}). Peak amplitudes almost always exceeded 1000 fluorescence units. LR-HPV type 6 was present in five samples, one of which, a cervical squamous cell carcinoma (SCC), uniquely contained the *E6/E7*genes from types 6 and 11 but not from any HR-HPV. This was the only specimen to contain HPV11.

###### 

HPV types in clinical samples

                                                                         LR-HPV   HR-HPV                                                                                                                                                       
  ----------------------- --------- --------- -------------- ----------- -------- -------- -------- -------- ------- -------- ------- ------- ------- -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
                                                                                                                                                                                                                                               
  **Cervical cytology**                                                                                                                                                                                                                        
  normal                  37        37        9 (24%)        3 (8%)      1        0        1        2        0       0        0       0       1       0        0       1       0       3       1       0       1       2       1       0       0
  ASCUS^1^                12        12        6 (50%)        3 (25%)     0        0        0        3        0       0        1       0       1       3        1       1       0       0       0       0       0       0       0       0       1
  columnar atypia         1         1         1 (100%)       0           0        0        0        1        0       0        0       0       0       0        0       0       0       0       0       0       0       0       0       0       0
  CIN 1                   24        24        18 (78%)       6 (25%)     2        0        4        2        0       2        3       1       1       2        2       1       0       1       1       2       1       1       1       2       0
  CIN 2                   11        11        11 (100%)      4 (36%)     0        0        7        3        0       2        2       0       0       0        0       0       0       0       1       0       1       0       0       0       1
  CIN 3                   4         4         4 (100%)       2 (50%)     0        0        3        0        0       1        0       0       0       1        0       0       1       0       1       1       1       0       0       1       0
  SCC^2^                  9         9         9 (100%)       3 (33%)     0        0        3        1        0       2        2       0       0       1        0       2       0       1       1       1       1       0       0       0       0
  *subtotal*              *98*      *98*      *58*           *21*        *3*      *0*      *18*     *12*     *0*     *7*      *8*     *1*     *3*     *7*      *3*     *5*     *1*     *5*     *5*     *4*     *5*     *3*     *2*     *3*     *2*
                                                                                                                                                                                                                                               
  **FFPE**                                                                                                                                                                                                                                     
  CIN *NOS*               11        5         11 (100%)      2 (18%)     1        0        3        2        0       1        0       0       1       0        1       1       1       0       0       0       0       0       0       1       0
  SCC, cervix             23        13        23 (100%)      2 (9%)      0        0        14       2        0       2        0       0       0       1        0       0       0       2       0       1       0       0       0       0       0
  ADCA, cervix            10        5         9 (90%)        1 (10%)     0        0        5        3        0       0        0       0       0       1        0       0       0       0       0       1       1       0       0       0       0
                                                                                                                                                                                                                                               
  *subtotal*              *44*      *23*      *43*           *5*         *1*      *0*      *22*     *7*      *0*     *3*      *0*     *0*     *1*     *2*      *1*     *1*     *1*     *2*     *0*     *2*     *1*     *0*     *0*     *1*     *0*
                                                                                                                                                                                                                                               
  **FTA**                                                                                                                                                                                                                                      
  SCC^3^                  23        23        22 (96%)       1 (4%)^4^   1        1        14       1        0       1        1       1       0       2        0       1       1       1       1       0       0       0       1       1       0
  ADCA^5^                 11        11        11 (100%)      1 (9%)      0        0        5        4        0       2        0       0       0       0        0       0       0       0       0       1       0       0       0       0       0
  SCC neck metastasis     31^6^     31        10 (100%)^7^   0           0        0        9        0        1       0        0       0       0       0        0       0       0       0       0       0       0       0       0       0       0
                                                                                                                                                                                                                                               
  *subtotal*              *65*      *65*      *44*           *2*         *1*      *1*      *28*     *5*      *1*     *3*      *1*     *1*     *0*     *2*      *0*     *1*     *1*     *1*     *1*     *1*     *0*     *0*     *1*     *0*     *0*
                                                                                                                                                                                                                                               
  **total**               **207**   **186**   **145**        **29**      **5**    **1**    **68**   **24**   **1**   **13**   **9**   **2**   **4**   **11**   **4**   **7**   **3**   **8**   **6**   **7**   **6**   **3**   **3**   **5**   **2**

^1^Atypical squamous cells of undetermined significance.

^2^One bronchoalveolar lavage for a HPV59^+^SCC metastasis from cervix cancer is included.

^3^Includes 5 FTA imprints from consecutively resected cervical SCC (3 primary, 2 metastatic nodes) and 18 consecutive surface tumors swabbed *in vivo*.

^4^Both low-risk HPV types 6 and 11 E6/E7 were present in a cervical SCC from an elderly woman.

^5^Includes 6 FTA imprints from consecutively excised tumors (5 primary, 1 metastatic node) and 5 consecutive ADCA swabbed *in vivo*.

^6^Primary tumors were located in the oropharynx (11), mesopharynx (2), nasopharynx (3), tongue (1), larynx (3), oral cavity (1), paranasal sinus (1), preauricular skin (3) and unknown sites (6).

^7^HPV^+^metastases were derived from 6 primary tumors in the oropharynx (5 tonsillar and 1 base of tongue) and 4 unknown sites. HPV26 was found in atypical squames in a neck node without a confirmed diagnosis of carcinoma but is included among SCC of unknown origin.

![**MPCR electropherogram in multiple infection**. An autoscaled electropherogram of a single CIN 3 sample contained HPV *E6/E7*types 16, 31, 45, 59 and 66, which are resolved in three panels, each representing a separate color channel (a red size marker channel is not shown). The X-axis indicates product size in nucleotides and the Y-axis shows fluorescence intensity in arbitrary units. The upper panel contains a single blue peak at 169 nt, corresponding to HPV59. In the middle panel, green peaks at 121, 210 and 268 nt confirm HPV31, HPV16 and the β-globin control, respectively. The bottom panel\'s black peak at 106 nt indicates HPV45 and the second peak at 121 nt matches HPV66. In the routine electropherogram with composite channels, peaks for types 31 and 66 overlap but are easily identified by color.](1750-9378-6-1-1){#F1}

About one-fourth of 37 consecutive samples with normal cytology were infected with HR-HPV and three of these (8%) had multiple genotypes. In 15 consecutive exfoliative samples of high-grade CIN (grades 2 and 3), one or more HR-HPVs occurred in all in the following order of frequency (slash indicates equal frequencies): types 16, 18/31, 33/58/66 and 45/53/59/73/82.

HPV *E6/E7*genes were detected in 75 of 76 primary or metastatic cervical carcinomas (21 adenocarcinomas \[ADCA\], 55 SCC, including the single SCC containing LR-HPV only), as single infections in 91%. The one negative sample was a β-globin^+^ADCA (de-identification prevented confirmation of a true primary cervical tumor in this case). HPV16 and 18 accounted for 69% of the 75 HPV-associated cervical cancers, and other genotypes were in order of frequency: 31, 45, 56/59, 33/52, 58/66 and 35/53/70, which accords with the national statistics \[[@B12]\].

Coinfection with more than one HPV type occurred less often in carcinomas in contrast to dysplastic cytology specimens, consistent with decreased rates of multiple infections among the generally older patients with carcinoma.

Nine of 31 nodal aspirates of SCC metastases from head and neck tumors (Table [2](#T2){ref-type="table"} footnotes 6 and 7) contained HPV. The primary site in HPV^+^tumors was oropharyngeal in six instances, consistent with previous studies \[[@B13]\], and the origin was unknown in three. All nine aspirates produced prominent HPV16 peaks only, confirming the overwhelming preponderance of this genotype and the reported lack of HPV18 in oropharyngeal SCC \[[@B14]\]. HPV26, a suspected HR-HPV \[[@B8]\] previously reported in extracervical SCC \[[@B15]\], was unexpectedly detected as the sole type in one nodal aspirate containing atypical squames but without a confirmed cancer diagnosis. This result was reconfirmed in a singleplex PCR on the same aspirate using HPV26 primers.

HR-HPV26, 39, 51, 68 and 82 were not present in this series of cervical carcinomas. Types 26, 53, 70, 73 and 82 are often not included in PCR protocols, partly due to inconclusive evidence of an overincidence in cancer. In our series, these types occurred 14 times *in toto*. Among cervical SCC, HPV types 70 and 73 each occurred once, type 53 was found in one SCC together with type 45, while type 26 was not detected in any cervical material. The rationale for inclusion of type 70 in the MPCR as a HR-HPV is further bolstered by its genotypic and biologic relation with HR-HPV \[[@B9],[@B16]\]. Among cell samples with high-grade CIN, one harbored HPV82, 31 and 33 concomitantly and another contained HPV53, 58 and 73.

In contrast to MPCR\'s high clinical sensitivity in lesional samples, its analytical sensitivity in dilute plasmid-HPV templates was variable, partly depending on whether single or multiple targets were present. Generally, six of the eight most prevalent HPV types needed \>100 genome-equivalents/μL to elicit a definitive peak, especially if mixed with other plasmids, while half of the remaining genotypes were detected at a concentration 10-fold less (data not shown).

The MPCR was robust in clinical samples, producing readily interpretable peaks and results were reproducible on repeat runs. An occasional small spurious peak due to saturation of the laser detector disappeared after diluting the product.

Secondary peaks attributable to primer cross-annealing appeared occasionally, mainly in cervical cytology specimens (presumably the result of higher virus loads in productive infections), but did not correspond in size and color to true peaks and had amplitudes usually below our cutoff. In theory, mispriming of a forward primer could result in an additional peak for a given HPV type, while a mispriming reverse primer could present a new peak of the same or different size and color (all fluorophores were regularly placed on the reverse primer) as the target peak.

Forward primers in types 39, 59, 68 and 70, which are all 20-mers and share 3 to 7 nt in their 3\' end sequence, might offer potential mispriming among their intended targets, which would not necessarily produce a peak shift related to anomalous product sequence and none was seen in electropherograms with these genotypes. Moreover, use of the \"touchdown\" technique in initial PCR cycles probably abrogated any tendency of this limited sequence similarity to competitively inhibit visualization of mixed infection. For example, two mixed HPV68/70 infections were easily detected.

*In silico*analysis of individual E6/E7 target sequences queried for significant complementarity (\> 85% overall complementarity with a requirement for complete complementarity in the last three 3\' bases) with any of the primers in the master mix yielded 29 potential misprimed products of varying size and color derived from 16 of the 21 genotypes when testing clinical material, none of which were of the same size but different color from that expected for the target. Complete complementarity was noted only for HPV31, where its forward primer amplified type 31 E6/E7 in conjunction with the predicted homologous type 16 reverse primer. Thus, HPV31 gave the most significant and consistent secondary peak (Table [2](#T2){ref-type="table"} footnote 4). Other predicted spurious amplicons included HPV66 annealing with its legitimate forward primer and type 56 reverse primer (91% complementarity) to yield a green product 1 to 2 nt larger than that of HPV68. Nonetheless, in no case was an apparent type 68 peak (three instances) found together with type 66 (six instances). HPV35, if annealed to the 52 reverse primer (91% complementarity) could yield an amplicon similar to HPV52 but this combination of products was not seen either.

Discussion
==========

We developed a primer-rich MPCR which offers single-tube economy and straightforward simplicity in genotyping 21 potentially oncogenic HPV using type-specific *E6/E7*primers. This broad spectrum and the short resulting amplicons necessary for formalin-degraded tumor specimens yielded a clinical sensitivity of 100% for high-grade CIN and 99% for cervical carcinoma, which clearly exceeds the HR-HPV detection rate reported for general primers when product detection is limited to the most common genotypes \[[@B17]\]. The reasons for failure of consensus capsid primers to amplify their target include relatively frequent base substitutions and deletions which may affect primer annealing or probe hybridization \[[@B2],[@B18]-[@B20]\]. Importantly, our MPCR targets the *sine qua non*of cervical tumorigenesis, the *E6/E7*oncogenes \[[@B21],[@B22]\]. Selection pressure appears to be minimal in codons within the *E6/E7*transition zone and sequence variations in the HPV16 *E6*gene, for example, tend largely to involve single nucleotides upstream of the primer region we used in all 21 genotypes \[[@B21]\].

Cervical cancer cell nuclei contain viral DNA either integrated in the host cell genome, as free episomes or both. If viral episomes disappear, which occurs in 20% to 50% or more of tumor specimens, most consistently in HPV18-induced tumors \[[@B18]\], only residual integrated HPV DNA would remain in the host cell and this would include the obligate *E6/E7*oncogenes \[[@B2],[@B4]\]. A recently reported multiplex PCR targeting the *E7*oncogene showed greater analytical sensitivity than PCR with broad-spectrum consensus *L1*primers where product detection in both analyses used bead-based hybridization (Luminex) \[[@B23]\]. In the single SCC in which our MPCR detected both HPV6 and 11 (footnote 2, Table [2](#T2){ref-type="table"}), general *L1*primers (GP5+/6+) in a PCR on the same patient sample followed by bead-based hybridization typing identified HPV6 but failed to identify HPV11, whereas a singleplex PCR with our type 11 *E6/E7*primers repeatedly confirmed the original result.

When compared with cytology, HPV genotyping by PCR offers higher sensitivity but lower specificity in detecting intraepithelial neoplasia \[[@B24]\] and PCR genotyping has been introduced as a means of triaging in cervical cancer screening programs. Ultimately, molecular methods may replace cytologic screening, in which case longitudinal testing using different PCR protocols may be expected to yield conflicting results. This makes a single, uniform, highly sensitive and reliable platform desirable for use in all relevant specimens, regardless of where in the diagnostic chain the specimen is obtained: screening, tissue biopsy/resection and eventual confirmation of metastasis by aspiration cytology or excision \[[@B25]-[@B28]\].

Our detection of rare HR-HPV in high-grade CIN and several suspected HR-HPV types in carcinoma points out that a relatively broad-spectrum multiplex PCR capable of typing all cervical carcinomas offers a desirable level of coverage but could still miss the rare tumor related to a low-risk HPV not covered in the analysis. In this regard, primers for additional genotypes could probably be added to the 46 already present in our MPCR without adversely affecting efficiency.

Although multiplex PCR with capillary electrophoresis gives lower analytical sensitivity, which would militate against its use in detecting infection per se or minimal residual malignant disease (cf., lymphproliferative diseases), in detection scenarios in the present study clinical sensitivity is more relevant and this was retained. If appropriately automated, scaled and tested on a larger population sample, our MPCR might be less likely to overburden triaging schemes with excessive detection of infections destined to resolve \[[@B29]\].

The cost of materials for the MPCR (unoptimized for use in screening) including primers and reagents, was about USD 7 per sample as of the year 2008.

Conclusions
===========

A primer-rich PCR readily detects the *E6/E7*oncogenes of 21 HPV types in fresh and fixed cytology and tissue specimens. The method is straightforward, robust, avoids post-PCR sequencing and hybridization steps by using fragment size analysis and detects HPV with high sensitivity in significant HPV-related neoplasia regardless of specimen type.

Methods
=======

Primer and product details
--------------------------

Primer parameters were adjusted to yield as many amplicons separated in size by \~3 or more nucleotides as possible while maintaining high PCR efficiency. Primer pairs were chosen to avoid potential duplex formation within and between pairs. Each primer pair with amplicon was used in a BLAST query of human and viral databases <http://www.ncbi.nlm.nih.gov/tools/primer-blast/> to confirm the sequence\'s uniqueness for each HPV genotype and to adjust primers for minor polymorphisms in primer binding sites reported for subtype variants. All reverse primers were synthesized with 5\' labels (FAM, blue; HEX, green or NED, black), which were alternated with each increase in corresponding amplicon size. Primers for the human β-globin control gene were designed to yield a green 268 nt product. The result was 46 unique primers designed to yield short products suitable for both high-molecular weight DNA and formalin-fixed material; expected HPV product sizes ranged from 94 to 258 nt with all but two being≤190 nt. Primer sets were then synthesized and purified by HPLC (Eurofins MWG/Operon, Germany).

PCR protocol
------------

DNA was extracted from sections and from cytology fluid using a kit (GentraSystems, USA) according to the manufacturer\'s instructions. DNA was precipitated in isopropanol, the pellet resuspended in 10 mM Tris-buffer, pH 8.5 and 50-100 ng was used as template.

After extensive testing in \>400 PCR using single and combined primer pairs, an optimal MPCR, capable of detecting at least 5 genotypes simultaneously in a single tube, was determined. It used 25 μL of (obligatory) Multiplex PCR Kit^®^(cat. no. 206143, Qiagen, Germany) in a 50 μL reaction, which included 5 μL of a solution containing 0.3 μM of each forward and reverse primer for β-globin and HPV types 16, 39, 66 and 68 with 0.2 μM for all other primers. After 15 min at 95°C, 8 \"touchdown\" cycles (1°C decline in annealing temperature for each succeeding cycle) were run starting with annealing at 65°C for 90 s in the first cycle, then 95°C, 30 s; 65°C -1°C, 90 s for seven cycles; 72°C, 45 s, and 22 cycles with constant parameters (95°C, 30 s; 57.5°C, 90 s; 72°C, 45 s) with a final extension at 68°C for 15 min. All *E6/E7*oligonucleotide targets were detected singly and in mixed combinations of 4 or 5 genotypes at estimated concentrations of 1.5 × 10^3^to 1.5 × 10^5^virus equivalents per genotype per μL.

Capillary electrophoresis
-------------------------

One μl of PCR product was added to a mixture of 12 μl formamide and 0.5 μl ROX 500 size standard prior to heat-denaturation and loading on an ABI Prism^®^3130 Genetics Analyzer whose capillaries were filled with POP7 polymer (minimum runtime 18 min). Data files were analyzed in GeneMarker^®,^vers. 1.75. Peaks were called if they were \~1 nt or less in width, corresponded to the predetermined size (± 0.5 nt) and color of a given genotype and were ≥500 fluorescence units to allow ready distinction from baseline.
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